# Tocilizumab for Patients With Giant Cell Arteritis

> **NCT01450137** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 30 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Tocilizumab + Glucocorticoids (GCs)
- **DRUG:** Placebo + Glucocorticoids (GCs)

## Key facts

- **NCT ID:** NCT01450137
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-12
- **Final completion:** 2015-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450137, "Tocilizumab for Patients With Giant Cell Arteritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01450137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*